Scarica l'app Stockscreener
58.47
4.37%
2.45
Pre-mercato:
59.10
0.63
+1.08%
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio earnings ahead: First results as royalty company - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Pass Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Anaptysbio Stock Price Forecast. Should You Buy ANAB? - StockInvest.us
Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A - Stock Titan
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio Announces Results of 2026 Annual Stockholders Meeting Voting - Kalkine Media
Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings? - Sahm
Price-Driven Insight from (ANAB) for Rule-Based Strategy - Stock Traders Daily
AnaptysBio (ANAB) Rallies 3.36% as Biotech Momentum Builds Toward Key ResistanceGolden Cross - dars.gov.et
AnaptysBio (ANAB) awards CEO 53,334 performance stock units - Stock Titan
AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO - Stock Titan
AnaptysBio Inc (ANAB) Stock News Today - TradingKey
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? - Investing.com
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com - Investing.com Canada
AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring a 59% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
ANAB Q2'26 Earnings: revenue estimate is 17.33M USD - TradingView
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute - The Globe and Mail
AnaptysBio and Tesaro set post-trial briefing schedule after July 2026 trial - TradingView
AnaptysBio: The Royalty Waterfall Is About To Reverse - Seeking Alpha
Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AnaptysBio, Inc. Revenue Breakdown – NASDAQ:ANAB - TradingView
ANAB|AnaptysBio Inc|Price:56.610|Chg%:+1.840 - TradingKey
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Cash Flow - TradingKey
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANAB|AnaptysBio Inc|Price:53.486|Chg%:-0.124 - TradingKey
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760 - TradingKey
TradingKey - TradingKey
AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC - MarketBeat
ANAB|AnaptysBio Inc|Price:56.102|Chg%:+0.632 - TradingKey
AnaptysBio Inc (ANAB) Income Statement - TradingKey
Anaptysbio, Inc Net Worth (2026) - GuruFocus
Affinity Asset Advisors LLC Boosts Position in AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6%Here's What Happened - MarketBeat
Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
AnaptysBio Declines 2.14% as Shares Test Key Support ZoneVolatility Term Structure - dars.gov.et
AnaptysBio Q1 2026 Earnings: Significant EPS Miss as Pipeline Costs Weigh on ResultsEarnings Call Q&A - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) - The Globe and Mail
AnaptysBio (ANAB) Surges 6.9%: Potential Breakout or Resistance Test?Box Spread - dars.gov.et
AnaptysBio (NASDAQ:ANAB) Shares Down 6.2%Here's Why - MarketBeat
High Growth Tech Stocks In The US Market - simplywall.st
AnaptysBio, Inc.'s Equity Buyback announced on March 24, 2025 has expired with 3,444,079 shares, representing 11.5% for $68.63 million. - marketscreener.com
AnaptysBio (NASDAQ:ANAB) Trading 5.3% HigherShould You Buy? - MarketBeat
Is AnaptysBio (ANAB) Undervalued Following Its Jemperli Royalty Appeal And GSK Trial? - Sahm
AnaptysBio (NASDAQ:ANAB) Shares Gap DownWhat's Next? - MarketBeat
Significant Decline for AnaptysBio (ANAB) as Shares Drop Over 10% - GuruFocus
Barclays Keeps Their Buy Rating on AnaptysBio (ANAB) - The Globe and Mail
AnaptysBio (NASDAQ:ANAB) Shares Down 7%Time to Sell? - MarketBeat
What Makes AnaptysBio (ANAB) an Investment Bet? - Yahoo Finance
Laughing Water Capital Q2 2026 Letter - Seeking Alpha
Form 144 ANAPTYSBIO For: 13 July By Investing.com - Investing.com Australia
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):